Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Humira

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Leerink believes the recent selloff has made valuations attractive.

Barchart

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Investors Business Daily

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

The Independent UK

AbbVie's Humira Downfall Is Swift As Biosimilars Hammer Away At Sales

AbbVie stock crumbled Thursday after the first biosimilar to launch in the U.S. hammered away at Humira's legendary sales.

Investors Business Daily

AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

AbbVie Rises As Lagging Profit Outlook Better Than Feared In Humira Battle Year

AbbVie stock inched higher Thursday after the company reported mixed earnings and issued a light profit outlook.

Investors Business Daily

Top Fund Manager Found A Way To Make Money While Others Lose

Making money in an up market is easy. But showering investors with gains when stocks fall is far more challenging for the best mutual funds.

Investors Business Daily

AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff

AbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar copy. But AbbVie stock advanced.

Investors Business Daily

AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

WEKU

Good news for consumers, bad news for AbbVie as its blockbuster drug Humira faces competition

CHICAGO — One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult coming year for the Illinois company that makes it.

Chicago Tribune

How Far Will AbbVie's Humira Revenue Fall in 2023?

The world's best-selling drug begins losing patent protections next year. AbbVie's revenue could take years to recover.

The Street

Biosimilars Are Saving America $1 Billion Per Month

Competitive drug prices are great for consumers. Turns out, they're good for industry, too.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Morgan Stanley Upgrades Cigna On Humira Prospects

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

Benzinga

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Investors Business Daily

Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?

A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week.

Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AbbVie Sales Lag As Humira Competition Heats Up And U.S. Biosimilars Loom

AbbVie stock inched ahead Wednesday despite a sales miss for its biggest moneymaker, Humira, as biosimilar competition heats up.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.